DURHAM, N.C.--(BUSINESS WIRE)--Feb. 21, 2006--Aldagen, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared a clinical study for physicians led by Dr. Emerson Perin and Dr. James Willerson of the Texas Heart Institute at St. Luke’s Episcopal Hospital in Houston, Texas, to conduct a clinical trial using Aldagen’s ALDESORT product to isolate a unique stem cell population for therapy for advanced heart failure patients. It will be the first clinical trial involving this unique cell population for therapy for heart failure patients in the United States.
